title: [Harm reduction strategy in tobacco control].
abstract: Potentially reduced exposure products (PREPs), already sold in USA and in some European Countries, are low-nitrosamine cigarettes, low-nitrosamine smokeless tobacco (e.g., the Swedish Snus), cigarette-like products, and medicinal nicotine products. Even e-cigarette delivers nicotine. With the exception of snus and medicinal nicotine, studies on the health effects of PREPs have not been carried out, although some PREPs are already sold and promoted as products that effectively reduce health risks. Thus, a second disaster similar to that occurred for light cigarettes could happen in the next years. Only medicinal nicotine and snus could be valid candidates to become PREPs, even if they pose some significant health risks. The World Health Organization, following a precautionary approach, has recently published a list of 9 carcinogens or toxicants recommended for mandated lowering (the tobacco-specific nitrosamines NNN and NNK, acetaldehyde, acrolein, benzene, benzo[a]pyrene, 1-3 butadiene, carbon monoxide, formaldehyde), and 9 carcinogens or toxicants for monitoring in usual cigarettes (not PREPs), underlining that tobacco companies cannot use this reduction strategy as a promotional message, as it occurred for light cigarettes in the 70s and 80s. The present status quo, in which cigarettes are freely available, medicinal nicotine, being a drug, is available under a regulated market, and Snus is prohibited, actually denies smokers the right to choose safer nicotine products. The solution suggested by the UK Royal College of Physicians is to balance the nicotine market, framing tobacco products and medicinal nicotine in the same regulation system; establishing a nicotine and tobacco regulatory authority;making medicinal nicotine more available; evaluating the feasibility of the introduction in the English market of Swedish Snus. California Government remarks that the nicotine maintenance is not a valid strategy, because it could induce smokers not to try to quit.Thus, California Department of Health Services prohibits promotion of snus and medicinal nicotine as a harm reduction strategy. However, the US Federal Family Smoking Prevention and Tobacco Control Act, signed by President Obama in 2009, places tobacco products under FDA jurisdiction: FDA must define criteria for lowering carcinogens and toxicants in tobacco products, making more available medicinal nicotine, evaluating PREPs, creating a federal Tobacco Control Agency.Which approaches is Italy going to follow?
authors.affiliation: SC Epidemiologia ambientale occupazionale - ISPO, Firenze. g.gorini@ispo.toscana.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Gorini
mesh_terms: D015415:Biomarkers; D002140:California; D002273:Carcinogens / Q000032:analysis; D005060:Europe; D005544:Forecasting; D040261:Harm Reduction; D006801:Humans; D007558:Italy; D009538:Nicotine / Q000008:administration & dosage; D012906:Smoke / Q000032:analysis; D012907:Smoking / Q000097:blood; D016540:Smoking Cessation / Q000331:legislation & jurisprudence*; D000074606:Smoking Prevention; D061485:Tobacco Use Cessation Devices / Q000145:classification / Q000706:statistics & numerical data; D014029:Tobacco Use Disorder / Q000097:blood / Q000517:prevention & control; D014030:Tobacco, Smokeless; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D015415:Biomarkers; D002273:Carcinogens; D012906:Smoke; D009538:Nicotine